Literature DB >> 32643515

Characterization of humoral and cellular immune features of gamma-irradiated influenza vaccine.

Fengjia Chen1, Ho Seong Seo1,2, Hyun Jung Ji1,3, Eunji Yang4, Jung Ah Choi4, Jae Seung Yang4, Manki Song4, Seung Hyun Han3, Sangyong Lim1,2, Jae Hyang Lim5,6, Ki Bum Ahn1.   

Abstract

The most widely used influenza vaccines are prepared by chemical inactivation. However, chemical, especially formalin, treatment-induced modifications of the antigenic structure of the virus are frequently associated with adverse effects including low efficacy of protection, unexpected immune responses, or exacerbation of disease. Gamma-irradiation was suggested as an alternative influenza virus inactivation method due to its great features of completely inactivating virus while not damaging the structures of protein antigens, and cross-protective ability against heterologous strains. However, immunological features of gamma radiation-inactivated influenza vaccine have not been fully understood. In this study, we aimed to investigate the humoral and cellular immune responses of gamma radiation-inactivated influenza vaccine. The gamma irradiation-inactivated influenza vaccine (RADVAXFluA) showed complete viral inactivation but retained normal viral structure with functional activities of viral protein antigens. Intranasal immunization of RADVAXFluA provided better protection against influenza virus infection than formalin-inactivated influenza virus (FIV) in mice. RADVAXFluA greatly enhanced the production of virus-specific serum IgG and alveolar mucosal IgA, which effectively neutralized HA (hemagglutinin) and NA (neuraminidase) activities, and blocked viral binding to the cells, respectively. Further analysis of IgG subclasses showed RADVAXFluA-immunized sera had higher levels of IgG1 and IgG2a than those of FIV-immunized sera. In addition, analysis of cellular immunity found RADVAXFluA induced strong dendritic cells (DC) activation resulting in higher DC-mediated activation of CD8+ T cells than FIV. The results support improved immunogenicity by RADVAXFluA.

Entities:  

Keywords:  Influenza A virus; dendritic cells; gamma-irradiation; mucosal immunity; whole cell inactivated vaccine

Year:  2020        PMID: 32643515      PMCID: PMC7899634          DOI: 10.1080/21645515.2020.1780091

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  62 in total

1.  Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.

Authors:  Ayato Takada; Sachiko Matsushita; Ai Ninomiya; Yoshihiro Kawaoka; Hiroshi Kida
Journal:  Vaccine       Date:  2003-07-04       Impact factor: 3.641

2.  On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice.

Authors:  P Parham
Journal:  J Immunol       Date:  1983-12       Impact factor: 5.422

3.  Development of a new hydrogen peroxide–based vaccine platform.

Authors:  Ian J Amanna; Hans-Peter Raué; Mark K Slifka
Journal:  Nat Med       Date:  2012-06       Impact factor: 53.440

Review 4.  Return of inactivated whole-virus vaccine for superior efficacy.

Authors:  Yoichi Furuya
Journal:  Immunol Cell Biol       Date:  2011-08-16       Impact factor: 5.126

5.  Vaccination with irradiated Listeria induces protective T cell immunity.

Authors:  Sandip K Datta; Sharon Okamoto; Tomoko Hayashi; Samuel S Shin; Ivan Mihajlov; Agnes Fermin; Donald G Guiney; Joshua Fierer; Eyal Raz
Journal:  Immunity       Date:  2006-07       Impact factor: 31.745

Review 6.  Defense mechanisms against influenza virus infection in the respiratory tract mucosa.

Authors:  Shin-ichi Tamura; Takeshi Kurata
Journal:  Jpn J Infect Dis       Date:  2004-12       Impact factor: 1.362

7.  Heterologous protection against influenza by injection of DNA encoding a viral protein.

Authors:  J B Ulmer; J J Donnelly; S E Parker; G H Rhodes; P L Felgner; V J Dwarki; S H Gromkowski; R R Deck; C M DeWitt; A Friedman
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

8.  Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes.

Authors:  F Gotch; A McMichael; G Smith; B Moss
Journal:  J Exp Med       Date:  1987-02-01       Impact factor: 14.307

Review 9.  Understanding MHC class I presentation of viral antigens by human dendritic cells as a basis for rational design of therapeutic vaccines.

Authors:  Nadine van Montfoort; Evelyn van der Aa; Andrea M Woltman
Journal:  Front Immunol       Date:  2014-04-23       Impact factor: 7.561

10.  Chemical and physical basics of routine formaldehyde fixation.

Authors:  Rooban Thavarajah; Vidya Kazhiyur Mudimbaimannar; Joshua Elizabeth; Umadevi Krishnamohan Rao; Kannan Ranganathan
Journal:  J Oral Maxillofac Pathol       Date:  2012-09
View more
  4 in total

1.  Radiation-Inactivated S. gallinarum Vaccine Provides a High Protective Immune Response by Activating Both Humoral and Cellular Immunity.

Authors:  Hyun Jung Ji; Eui-Baek Byun; Fengjia Chen; Ki Bum Ahn; Ho Kyoung Jung; Seung Hyun Han; Jae Hyang Lim; Yongkwan Won; Ja Young Moon; Jin Hur; Ho Seong Seo
Journal:  Front Immunol       Date:  2021-08-16       Impact factor: 7.561

Review 2.  Advances in Irradiated Livestock Vaccine Research and Production Addressing the Unmet Needs for Farmers and Veterinary Services in FAO/IAEA Member States.

Authors:  Hermann Unger; Richard T Kangethe; Fatima Liaqat; Gerrit J Viljoen
Journal:  Front Immunol       Date:  2022-03-28       Impact factor: 7.561

3.  Protective Efficacy of H9N2 Avian Influenza Vaccines Inactivated by Ionizing Radiation Methods Administered by the Parenteral or Mucosal Routes.

Authors:  Alessio Bortolami; Eva Mazzetto; Richard Thiga Kangethe; Viskam Wijewardana; Mario Barbato; Luca Porfiri; Silvia Maniero; Elisa Mazzacan; Jane Budai; Sabrina Marciano; Valentina Panzarin; Calogero Terregino; Francesco Bonfante; Giovanni Cattoli
Journal:  Front Vet Sci       Date:  2022-07-11

4.  Whole-cell vaccine candidates induce a protective response against virulent Acinetobacter baumannii.

Authors:  Stephen J Dollery; Daniel V Zurawski; Ruth V Bushnell; John K Tobin; Taralyn J Wiggins; David A MacLeod; Naomi J P E R Tasker; Yonas A Alamneh; Rania Abu-Taleb; Christine M Czintos; Wanwen Su; Mariel G Escatte; Heather N Meeks; Michael J Daly; Gregory J Tobin
Journal:  Front Immunol       Date:  2022-09-27       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.